Trial Profile
A phase I study of SU5416 [semaxanib] in combination with gemcitabine/cisplatin in patients with advanced solid tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Semaxanib (Primary) ; Cisplatin; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- 11 Sep 2005 New trial record.